# A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Source: https://onco.cc/trials/nct04306224/  
OnCo record `nct04306224` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of IMC-002 run by ImmuneOncia Therapeutics Inc., completed.

## Summary

A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas is a phase 1 interventional study registered as NCT04306224 by ImmuneOncia Therapeutics Inc., with 12 participants enrolled, started 2020-06-05. Conditions recorded: Solid Tumor and Lymphoma. Interventions recorded: IMC-002.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04306224
- Phase: 1
- Setting: A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
- Sponsor: ImmuneOncia Therapeutics Inc.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT04306224: https://clinicaltrials.gov/study/NCT04306224

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [IMC-002](https://onco.cc/drugs/imc-002/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04306224.json